COMPANY

Thetis Pharmaceuticals LLC

thetispharma.com ↗

Clinical Phase 1

Also known as Thetis Pharmaceuticals · 6 sources

Keywords: oncology Ulcerative Colitis Non-Insulin-Dependent Diabetes Mellitus Hypertriglyceridemia TP317

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $560K in debt securities (Form D filed Oct 13, 2026). SEC Form D 0001528491-26-000003 (Oct 13, 2026)
Evidence (1 event)
- Oct 13, 2026 · SEC Form D 0001528491-26-000003
  Name of Issuer: Thetis Pharmaceuticals LLC; CIK: 1528491; Address: Deep River, CT; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-13; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 560300; Federal exemptions: 06b
NIH award NIH awarded $670K (SBIR commercialization 1SB1DK145287-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $941K in the last 12 months. NIH RePORTER 1SB1DK145287-01A1 (Sep 17, 2026)
Evidence (2 events)
- Sep 17, 2026 · NIH RePORTER 1SB1DK145287-01A1
  Organization: THETIS PHARMACEUTICALS, LLC; City/State: DEEP RIVER, CT; Project number: 1SB1DK145287-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 669925; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of TP-317 for Ulcerative Colitis; Organization type: Domestic For-Profits
- Jul 6, 2026 · NIH RePORTER 5R44CA278026-03
  Organization: THETIS PHARMACEUTICALS, LLC; City/State: DEEP RIVER, CT; Project number: 5R44CA278026-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 271378; Administering IC: National Cancer Institute; Project title: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 17, 2026 Grant Government grant — SBIR: $669,925 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 16, 2026 Trial start 1: Phase 1b Clinical Study in Patients With Active Ulcerative Colitis source ↗
Jul 6, 2026 Grant Government grant — SBIR: $271,378 (annual award, as published), announced Jul 6, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 8, 2025 Grant Government grant — SBIR: $1.73M (annual award, as published), announced Sep 8, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Apr 16, 2025 Grant Government grant — SBIR: $999,696 (annual award, as published), announced Apr 16, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
2014-03 Trial start Phase 1: PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA source ↗

Upcoming milestones

Jul 29, 2027 (ESTIMATED) · 1 · Phase 1b Clinical Study in Patients With Active Ulcerative Colitis · NCT07834515

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $669,925 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Jul 6, 2026 Government grant — SBIR: $271,378 (annual award, as published), announced Jul 6, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 8, 2025 Government grant — SBIR: $1.73M (annual award, as published), announced Sep 8, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Apr 16, 2025 Government grant — SBIR: $999,696 (annual award, as published), announced Apr 16, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07834515	Phase 1b Clinical Study in Patients With Active Ulcerative Colitis	1	Not yet recruiting	Sep 16, 2026	Jul 29, 2027 (estimated)
NCT02113163	PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA	Phase 1	Completed	2014-03	2014-06 (actual)